that seems like a massive tick, advantage for MPL ands good decision for management to target neuro degenerative diseases, if MPL proves effective for MND and it’s ability to cross the BBB is the key then what is next, the SP predictions of $$ might not sound so far fetched.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-166
-
- There are more pages in this discussion • 1,259 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.22M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $244.3K | 1.244M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 257206 | 7 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |